Control Bionics Limited (ASX:CBL)

Australia flag Australia · Delayed Price · Currency is AUD
0.0590
-0.0030 (-4.84%)
At close: Mar 6, 2026
47.50%
Market Cap 24.31M
Revenue (ttm) 6.07M
Net Income (ttm) -6.50M
Shares Out 411.96M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 36,939
Average Volume 269,521
Open 0.0590
Previous Close 0.0620
Day's Range 0.0590 - 0.0590
52-Week Range 0.0260 - 0.0860
Beta 0.02
RSI 49.10
Earnings Date Feb 23, 2026

About Control Bionics

Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. The company also provides the NeuroStrip, a wearable, miniaturized electromyogr... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2005
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol CBL
Full Company Profile

Financial Performance

In fiscal year 2025, Control Bionics's revenue was 6.14 million, an increase of 14.84% compared to the previous year's 5.35 million. Losses were -6.11 million, 3.30% more than in 2024.

Financial Statements

News

There is no news available yet.